<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.48.0">
<page number="1" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="0" size="10" family="Times" color="#231f20"/>
	<fontspec id="1" size="16" family="Times" color="#231f20"/>
	<fontspec id="2" size="14" family="Times" color="#231f20"/>
	<fontspec id="3" size="14" family="Times" color="#231f20"/>
	<fontspec id="4" size="22" family="Times" color="#231f20"/>
	<fontspec id="5" size="25" family="Times" color="#231f20"/>
	<fontspec id="6" size="7" family="Times" color="#231f20"/>
	<fontspec id="7" size="14" family="Times" color="#231f20"/>
<text top="108" left="106" width="210" height="12" font="0">Archives of the Balkan Medical Union</text>
<text top="122" left="106" width="226" height="12" font="0">Copyright © 2019 Balkan Medical Union</text>
<text top="108" left="635" width="151" height="12" font="0">vol. 54, no. 2, pp. 345-350</text>
<text top="122" left="728" width="59" height="12" font="0">June 2019</text>
<text top="652" left="457" width="12" height="18" font="1">R</text>
<text top="656" left="469" width="43" height="13" font="0">ÉSUMÉ</text>
<text top="687" left="457" width="186" height="19" font="2"><b>Le syndrome de Budd-Chiari</b></text>
<text top="724" left="457" width="334" height="19" font="3">Le syndrome de Budd-Chiari (BCS) est une maladie </text>
<text top="743" left="457" width="329" height="19" font="3">rare caractérisée par une obstruction des veines hépa-</text>
<text top="762" left="457" width="334" height="19" font="3">tiques, quels que soient leur mécanisme et leur degré, </text>
<text top="781" left="457" width="329" height="19" font="3">en l’absence de maladie cardiaque, de maladie péri-</text>
<text top="799" left="457" width="333" height="19" font="3">cardique ou de syndrome obstructif sinusoïdal. En ce </text>
<text top="818" left="457" width="333" height="19" font="3">qui concerne l’étiologie, le BCS est classé dans le BCS </text>
<text top="837" left="457" width="330" height="19" font="3">primaire, lorsqu’il est provoqué par une thrombose in-</text>
<text top="856" left="457" width="329" height="19" font="3">travasculaire, et le BCS secondaire, lorsque l’obstruc-</text>
<text top="874" left="457" width="334" height="19" font="3">tion est due à une compression extrinsèque ou à une </text>
<text top="893" left="457" width="334" height="19" font="3">invasion tumorale. Le diagnostic positif repose sur les </text>
<text top="912" left="457" width="333" height="19" font="3">antécédents médicaux du patient, son examen clinique </text>
<text top="931" left="457" width="333" height="19" font="3">et ses investigations paracliniques. Le tableau clinique </text>
<text top="949" left="457" width="333" height="19" font="3">est polymorphe. La fièvre, les douleurs abdominales et </text>
<text top="968" left="457" width="330" height="19" font="3">la sensibilité abdominale à la palpation, l’hépatomé-</text>
<text top="987" left="457" width="335" height="19" font="3">galie, l’ascite, l’œdème des membres inférieurs, les </text>
<text top="1006" left="457" width="335" height="19" font="3">saignements gastro-intestinaux et l’encéphalopathie </text>
<text top="652" left="106" width="12" height="18" font="1">A</text>
<text top="656" left="118" width="55" height="13" font="0">BSTRACT</text>
<text top="687" left="106" width="329" height="19" font="3">Budd-Chiari syndrome (BCS) is a rare disease charac-</text>
<text top="706" left="106" width="333" height="19" font="3">terized by obstruction of the hepatic veins, regardless of </text>
<text top="724" left="106" width="333" height="19" font="3">mechanism and degree, in the absence of heart disease, </text>
<text top="743" left="106" width="333" height="19" font="3">pericardial disease or sinusoidal obstructive syndrome. </text>
<text top="762" left="106" width="333" height="19" font="3">In relation to etiology, BCS is classified in primary </text>
<text top="781" left="106" width="330" height="19" font="3">BCS, when it is caused by an intravascular thrombo-</text>
<text top="799" left="106" width="333" height="19" font="3">sis, and secondary BCS, when the obstruction is due to </text>
<text top="818" left="106" width="333" height="19" font="3">extrinsic compression or tumor invasion. The positive </text>
<text top="837" left="106" width="329" height="19" font="3">diagnosis is based on patient’s medical history, clini-</text>
<text top="856" left="106" width="334" height="19" font="3">cal examination, and paraclinical investigations. The </text>
<text top="874" left="106" width="334" height="19" font="3">clinical picture is polymorphous. The most common </text>
<text top="893" left="106" width="333" height="19" font="3">signs and symptoms include fever, abdominal pain and </text>
<text top="912" left="106" width="330" height="19" font="3">abdominal tenderness on palpation, hepatomegaly, as-</text>
<text top="931" left="106" width="330" height="19" font="3">cites, edema of the lower limbs, gastrointestinal bleed-</text>
<text top="949" left="106" width="334" height="19" font="3">ing and hepatic encephalopathy. Laboratory tests can </text>
<text top="968" left="106" width="333" height="19" font="3">detect the degree of liver injury, with decreased serum </text>
<text top="987" left="106" width="335" height="19" font="3">albumin, altered coagulation, hepatic cytolysis and </text>
<text top="1006" left="106" width="333" height="19" font="3">cholestasis, while imaging investigations may reveal the </text>
<text top="200" left="653" width="133" height="24" font="4">MINIREVIEW</text>
<text top="311" left="106" width="309" height="27" font="5">BUDD-CHIARI SYNDROME</text>
<text top="363" left="106" width="123" height="17" font="3">Gina GHEORGHE</text>
<text top="362" left="229" width="6" height="10" font="6">1</text>
<text top="363" left="236" width="110" height="17" font="3">, Madalina ILIE</text>
<text top="362" left="346" width="18" height="10" font="6">1,2 </text>
<text top="363" left="364" width="123" height="17" font="3">, Bogdan SOCEA</text>
<text top="362" left="488" width="15" height="10" font="6">2,3</text>
<text top="363" left="503" width="192" height="17" font="3">, Ana Maria A. STANESCU</text>
<text top="362" left="695" width="6" height="10" font="6">2</text>
<text top="363" left="701" width="10" height="17" font="3">, </text>
<text top="381" left="106" width="123" height="17" font="3">Ovidiu G. BRATU</text>
<text top="381" left="229" width="15" height="10" font="6">2,4</text>
<text top="381" left="244" width="143" height="17" font="3">, Mihaela A. IANCU</text>
<text top="381" left="387" width="6" height="10" font="6">2</text>
<text top="381" left="393" width="151" height="17" font="3">, Mihaela C. OLARIU</text>
<text top="381" left="544" width="15" height="10" font="6">2,5</text>
<text top="381" left="559" width="156" height="17" font="3">, Gheorghe CIOBANU</text>
<text top="381" left="715" width="6" height="10" font="6">6</text>
<text top="381" left="721" width="10" height="17" font="3">, </text>
<text top="400" left="106" width="155" height="17" font="3">Camelia C. DIACONU</text>
<text top="399" left="261" width="18" height="10" font="6">1,2 </text>
<text top="425" left="106" width="5" height="11" font="6">1</text>
<text top="424" left="111" width="414" height="19" font="3"> Clinical Emergency Hospital of Bucharest, Bucharest, Romania</text>
<text top="443" left="106" width="5" height="11" font="6">2</text>
<text top="443" left="111" width="485" height="19" font="3"> University of Medicine and Pharmacy “Carol Davila“, Bucharest, Romania</text>
<text top="462" left="106" width="5" height="11" font="6">3</text>
<text top="461" left="111" width="523" height="19" font="3"> Emergency Clinical Hospital „Sf. Pantelimon“, General Surgery Clinic, Romania</text>
<text top="481" left="106" width="5" height="11" font="6">4</text>
<text top="480" left="111" width="680" height="19" font="3"> Emergency Universitary Central Military Hospital, Department of Urology, „Carol Davila“ University of </text>
<text top="499" left="106" width="295" height="19" font="3">Medicine and Pharmacy, Bucharest, Romania</text>
<text top="518" left="106" width="5" height="11" font="6">5</text>
<text top="518" left="111" width="487" height="19" font="3"> National Institute of Infectious Diseases „Matei Bals“, Bucharest, Romania</text>
<text top="537" left="106" width="5" height="11" font="6">6</text>
<text top="536" left="111" width="679" height="19" font="3"> Department of Emergency Medicine, State University of Medicine and Pharmacy ,,Nicolae Testemitanu“, </text>
<text top="555" left="106" width="206" height="19" font="3">Chisinau,  Republic of Moldova</text>
<text top="574" left="502" width="285" height="19" font="7"><i>Received 02 March 2019, Accepted 05 May 2019</i></text>
<text top="597" left="548" width="238" height="12" font="0">https://doi.org/10.31688/ABMU.2019.54.2.20</text>
<text top="1079" left="143" width="167" height="13" font="0"> Address for correspondence:  </text>
<text top="1079" left="348" width="112" height="13" font="0"> Camelia C. DIACONU</text>
<text top="1096" left="348" width="362" height="13" font="0">Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest, </text>
<text top="1113" left="348" width="109" height="13" font="0">Bucharest, Romania</text>
<text top="1131" left="348" width="287" height="13" font="0">Address: 8, Calea Floreasca Str, Bucharest, Romania</text>
<text top="1148" left="348" width="193" height="13" font="0">Email drcameliadiaconu@gmail.com</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="8" size="11" family="Times" color="#231f20"/>
	<fontspec id="9" size="13" family="Times" color="#231f20"/>
<text top="91" left="106" width="242" height="14" font="8">Budd-Chiari syndrome – GHEORGHE et al</text>
<text top="1182" left="106" width="143" height="14" font="8">346  /  vol. 54, no. 2</text>
<text top="558" left="106" width="5" height="18" font="1">I</text>
<text top="562" left="112" width="85" height="13" font="0">NTRODUCTION</text>
<text top="594" left="136" width="305" height="19" font="3">Budd-Chiari syndrome (BCS) is a congestive </text>
<text top="613" left="106" width="334" height="19" font="3">liver disease secondary to hepatic veins obstruction, </text>
<text top="632" left="106" width="333" height="19" font="3">due to either a thrombotic or a non-thrombotic event. </text>
<text top="650" left="106" width="334" height="19" font="3">The prognosis of patients with BCS ranges from a </text>
<text top="669" left="106" width="333" height="19" font="3">potential curability to death, as this syndrome may </text>
<text top="688" left="106" width="329" height="19" font="3">occur during the development of a severe hemato-</text>
<text top="707" left="106" width="244" height="19" font="3">logical disease or during malignancies</text>
<text top="708" left="350" width="12" height="11" font="6">1,2</text>
<text top="707" left="362" width="78" height="19" font="3">. The name </text>
<text top="726" left="106" width="334" height="19" font="3">of this syndrome comes from the English internist, </text>
<text top="745" left="106" width="334" height="19" font="3">George Budd, who in 1845 described the first three </text>
<text top="764" left="106" width="333" height="19" font="3">cases of venous hepatic thrombosis secondary to liver </text>
<text top="783" left="106" width="329" height="19" font="3">phlebitis induced by abscesses, and Austrian patholo-</text>
<text top="802" left="106" width="334" height="19" font="3">gist Hans Chiari, credited with the first pathological </text>
<text top="821" left="106" width="335" height="19" font="3">description of a liver with hepatic-vein-obstructive </text>
<text top="840" left="106" width="134" height="19" font="3">endo-phlebitis (1899).</text>
<text top="880" left="106" width="10" height="18" font="1">E</text>
<text top="883" left="117" width="82" height="13" font="0">PIDEMIOLOGY</text>
<text top="915" left="136" width="306" height="19" font="3">Budd-Chiari syndrome is a rare condition, </text>
<text top="934" left="106" width="334" height="19" font="3">its prevalence being estimated at about 1 case per </text>
<text top="953" left="106" width="314" height="19" font="3">100.000 inhabitants, with geographical variations</text>
<text top="953" left="421" width="11" height="11" font="6">3,4</text>
<text top="953" left="432" width="8" height="19" font="3">. </text>
<text top="972" left="106" width="333" height="19" font="3">Thus, in some Asian countries, such as Nepal, BCS </text>
<text top="990" left="106" width="329" height="19" font="3">is considered a relatively common cause of liver dis-</text>
<text top="1009" left="106" width="334" height="19" font="3">ease, while in Western countries it is a rare disease, </text>
<text top="1028" left="106" width="333" height="19" font="3">with an incidence not exceeding 1 case in 2.5 million </text>
<text top="1047" left="106" width="128" height="19" font="3">individuals per year</text>
<text top="1048" left="234" width="5" height="11" font="6">4</text>
<text top="1047" left="239" width="201" height="19" font="3">. BCS affects all races and the </text>
<text top="1066" left="106" width="269" height="19" font="3">male-to-female ratio is approximately equal</text>
<text top="1067" left="376" width="5" height="11" font="6">3</text>
<text top="1066" left="380" width="59" height="19" font="3">. Related </text>
<text top="1085" left="106" width="334" height="19" font="3">to geographical region, in Western countries hepatic </text>
<text top="1104" left="106" width="329" height="19" font="3">vein obstruction is more common, unlike non-West-</text>
<text top="1123" left="106" width="334" height="19" font="3">ern countries, where inferior vena cava obstruction </text>
<text top="1142" left="106" width="334" height="19" font="3">is encountered more frequently. In regions such as </text>
<text top="558" left="457" width="334" height="19" font="3">South Africa, India, Japan, Nepal and China, Budd </text>
<text top="577" left="457" width="333" height="19" font="3">Chiari syndrome is often caused by a membranous </text>
<text top="596" left="457" width="335" height="19" font="3">obstruction, while in the Western countries it is </text>
<text top="615" left="457" width="247" height="19" font="3">most commonly caused by thrombosis</text>
<text top="616" left="704" width="5" height="11" font="6">2</text>
<text top="615" left="709" width="82" height="19" font="3">. The initial </text>
<text top="634" left="457" width="333" height="19" font="3">theory claimed a congenital cause for the membrane, </text>
<text top="653" left="457" width="334" height="19" font="3">but currently there are opinions saying that this is a </text>
<text top="671" left="457" width="258" height="19" font="3">consequence of thrombosis organization</text>
<text top="672" left="715" width="5" height="11" font="6">5</text>
<text top="671" left="720" width="67" height="19" font="3">. One pos-</text>
<text top="690" left="457" width="334" height="19" font="3">sible trigger factor might be an infectious event. The </text>
<text top="709" left="457" width="334" height="19" font="3">symptoms of hepatic vein obstruction are similar to </text>
<text top="728" left="457" width="334" height="19" font="3">those of the liver segment of the inferior vena cava </text>
<text top="747" left="457" width="104" height="19" font="3">liver obstruction</text>
<text top="747" left="561" width="5" height="11" font="6">2</text>
<text top="747" left="566" width="4" height="19" font="3">.</text>
<text top="787" left="457" width="10" height="18" font="1">E</text>
<text top="790" left="467" width="50" height="13" font="0">TIOLOGY</text>
<text top="822" left="487" width="300" height="19" font="3">Depending on the origin of the obstructive le-</text>
<text top="841" left="457" width="329" height="19" font="3">sion, Budd-Chiari syndrome can be primary or sec-</text>
<text top="859" left="457" width="335" height="19" font="3">ondary. Thus, if the obstruction is the result of a </text>
<text top="878" left="457" width="330" height="19" font="3">lesion such as endoluminal thrombosis, BCS is con-</text>
<text top="897" left="457" width="330" height="19" font="3">sidered primary, while if the causes are either an ex-</text>
<text top="916" left="457" width="322" height="19" font="3">trinsic compression or invasion, it is secondary BCS</text>
<text top="917" left="778" width="5" height="11" font="6">1</text>
<text top="916" left="783" width="8" height="19" font="3">. </text>
<text top="935" left="457" width="329" height="19" font="3">Risk factors for the development of primary and sec-</text>
<text top="954" left="457" width="295" height="19" font="3">ondary BCS, respectively, are shown in Table 1</text>
<text top="954" left="752" width="5" height="11" font="6">2</text>
<text top="954" left="756" width="4" height="19" font="3">.</text>
<text top="972" left="487" width="305" height="19" font="3">Intravascular thrombosis is a major cause of </text>
<text top="991" left="457" width="330" height="19" font="3">hepatic venous obstruction. To initiate the patho-</text>
<text top="1010" left="457" width="334" height="19" font="3">logical process, the interaction between one or more </text>
<text top="1029" left="457" width="329" height="19" font="3">prothrombotic disorders and a trigger factor is nec-</text>
<text top="1048" left="457" width="335" height="19" font="3">essary. At least one prothrombotic risk factor has </text>
<text top="1066" left="457" width="295" height="19" font="3">been identified in 87% of patients with BCS</text>
<text top="1067" left="753" width="5" height="11" font="6">6</text>
<text top="1066" left="757" width="34" height="19" font="3"> and </text>
<text top="1085" left="457" width="321" height="19" font="3">up to 46% of the patients had multiple risk factors</text>
<text top="1086" left="778" width="5" height="11" font="6">6</text>
<text top="1085" left="783" width="8" height="19" font="3">. </text>
<text top="1104" left="457" width="334" height="19" font="3">Myeloproliferative neoplasms (MPN) are the main </text>
<text top="1123" left="457" width="43" height="19" font="3">culprit</text>
<text top="1124" left="501" width="5" height="11" font="6">2</text>
<text top="1123" left="506" width="286" height="19" font="3">. Of these, closely associated with hepatic </text>
<text top="1142" left="457" width="333" height="19" font="3">vein thrombosis is polycythemia vera, while essential </text>
<text top="126" left="457" width="335" height="19" font="3">hépatique sont les signes et les symptômes les plus </text>
<text top="145" left="457" width="334" height="19" font="3">courants. Les tests de laboratoire peuvent détecter le </text>
<text top="164" left="457" width="335" height="19" font="3">degré de lésion hépatique, avec une diminution de </text>
<text top="182" left="457" width="329" height="19" font="3">la sérum-albumine, une modification de la coagula-</text>
<text top="201" left="457" width="334" height="19" font="3">tion, une cytolyse hépatique et une cholestase, tandis </text>
<text top="220" left="457" width="329" height="19" font="3">que des examens d’imagerie peuvent révéler une obs-</text>
<text top="239" left="457" width="333" height="19" font="3">truction veineuse. En ce qui concerne le traitement, </text>
<text top="257" left="457" width="334" height="19" font="3">l’anticoagulation systémique est recommandée à tous </text>
<text top="276" left="457" width="333" height="19" font="3">les patients atteints de BCS afin de réduire le risque </text>
<text top="295" left="457" width="329" height="19" font="3">d’extension du thrombus et de prévenir d’autres épi-</text>
<text top="314" left="457" width="335" height="19" font="3">sodes thrombotiques. Selon les caractéristiques du </text>
<text top="332" left="457" width="333" height="19" font="3">patient, une angiographie avec ou sans endoprothèse </text>
<text top="351" left="457" width="329" height="19" font="3">vasculaire, une thrombolyse, un shunt portosysté-</text>
<text top="370" left="457" width="333" height="19" font="3">mique intrahépatique transjugulaire et une greffe du </text>
<text top="389" left="457" width="333" height="19" font="3">foie doivent être envisagés. La gravité et le pronostic du </text>
<text top="407" left="457" width="333" height="19" font="3">syndrome sont dictés par la maladie sous-jacente, allant </text>
<text top="426" left="457" width="266" height="19" font="3">d’une curabilité possible à une mort rapide.</text>
<text top="468" left="457" width="78" height="16" font="9">Mots-clés: </text>
<text top="464" left="538" width="252" height="19" font="3">syndrome de Budd-Chiari, obstruction </text>
<text top="482" left="457" width="329" height="19" font="3">veineuse hépatique, anticoagulants, shunt portosysté-</text>
<text top="501" left="457" width="226" height="19" font="3">mique intrahépatique transjugulaire.</text>
<text top="126" left="106" width="334" height="19" font="3">venous obstruction. Regarding treatment, all patients </text>
<text top="145" left="106" width="334" height="19" font="3">with BCS are recommended systemic anticoagulation </text>
<text top="164" left="106" width="329" height="19" font="3">to reduce the risk of thrombus extension and preven-</text>
<text top="182" left="106" width="334" height="19" font="3">tion of further thrombotic episodes. Depending on </text>
<text top="201" left="106" width="334" height="19" font="3">patient’s individual characteristics, angiography with </text>
<text top="220" left="106" width="330" height="19" font="3">or without stent, thrombolysis, trans-jugular intrahe-</text>
<text top="239" left="106" width="334" height="19" font="3">patic portosystemic shunt and liver transplant are to </text>
<text top="257" left="106" width="334" height="19" font="3">be considered. The syndrome’s severity and prognosis </text>
<text top="276" left="106" width="333" height="19" font="3">are dictated by the underlying disease, ranging from a </text>
<text top="295" left="106" width="206" height="19" font="3">possible curability to quick death.</text>
<text top="336" left="106" width="75" height="16" font="9">Keywords: </text>
<text top="332" left="184" width="252" height="19" font="3">Budd-Chiari syndrome, hepatic vein ob-</text>
<text top="351" left="106" width="334" height="19" font="3">struction, anticoagulants, trans-jugular intrahepatic </text>
<text top="370" left="106" width="127" height="19" font="3">portosystemic shunt.</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="10" size="13" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="8">Archives of the Balkan Medical Union</text>
<text top="1182" left="661" width="42" height="14" font="8">June </text>
<text top="1182" left="694" width="93" height="14" font="8">2019 / 347</text>
<text top="557" left="106" width="335" height="19" font="3">thrombocythemia and idiopathic myelofibrosis are </text>
<text top="576" left="106" width="131" height="19" font="3">less frequent causes</text>
<text top="576" left="237" width="5" height="11" font="6">7</text>
<text top="576" left="241" width="200" height="19" font="3">. Hyperhomocysteinemia and </text>
<text top="595" left="106" width="333" height="19" font="3">methylene-tetrahydrofolate reductase gene mutations </text>
<text top="613" left="106" width="330" height="19" font="3">(MTHFR) are less important risk factors for splanch-</text>
<text top="632" left="106" width="96" height="19" font="3">nic thrombosis</text>
<text top="633" left="203" width="5" height="11" font="6">8</text>
<text top="632" left="208" width="228" height="19" font="3">. Another risk factor for BCS is an-</text>
<text top="651" left="106" width="334" height="19" font="3">tiphospholipid antibodies syndrome, which can be </text>
<text top="670" left="106" width="334" height="19" font="3">associated with various connective tissue diseases. </text>
<text top="689" left="106" width="334" height="19" font="3">Consumption of oral contraceptives, pregnancy and </text>
<text top="708" left="106" width="330" height="19" font="3">confinement are risk factors for BCS, but most of-</text>
<text top="727" left="106" width="249" height="19" font="3">ten they coexist with other risk factors</text>
<text top="727" left="355" width="12" height="11" font="6">2,9</text>
<text top="727" left="366" width="74" height="19" font="3">. Although </text>
<text top="745" left="106" width="333" height="19" font="3">Behçet’s disease can cause hepatic vein thrombosis, it </text>
<text top="764" left="106" width="321" height="19" font="3">is more likely to cause inferior vena cava obstruction</text>
<text top="765" left="427" width="5" height="11" font="6">2</text>
<text top="764" left="432" width="8" height="19" font="3">. </text>
<text top="783" left="106" width="333" height="19" font="3">Inherited prothrombotic diseases (Table 1) have been </text>
<text top="802" left="106" width="333" height="19" font="3">described as risk factors for both BCS and portal vein </text>
<text top="821" left="106" width="70" height="19" font="3">thrombosis</text>
<text top="822" left="176" width="9" height="11" font="6">10</text>
<text top="821" left="185" width="255" height="19" font="3">. The major causes of secondary BCS are </text>
<text top="840" left="106" width="334" height="19" font="3">cancers and infections (Table 1). Uncommon causes </text>
<text top="859" left="106" width="330" height="19" font="3">are trauma, with the formation of intrahepatic hema-</text>
<text top="878" left="106" width="334" height="19" font="3">tomas, and granulomas caused by aspergillosis and </text>
<text top="896" left="106" width="259" height="19" font="3">sarcoidosis, that invade the hepatic veins.</text>
<text top="936" left="106" width="11" height="18" font="1">P</text>
<text top="940" left="117" width="82" height="13" font="0">ATHOLOGICAL</text>
<text top="936" left="199" width="5" height="18" font="1"> </text>
<text top="940" left="204" width="49" height="13" font="0">COURSE</text>
<text top="972" left="136" width="304" height="19" font="3">Obstruction of two or more major hepatic veins </text>
<text top="990" left="106" width="334" height="19" font="3">increases the sinusoidal pressure and reduces sinus </text>
<text top="1009" left="106" width="334" height="19" font="3">blood flow. An obstruction in only one hepatic vein </text>
<text top="1028" left="106" width="333" height="19" font="3">is generally clinically evident. The result of these </text>
<text top="1047" left="106" width="335" height="19" font="3">hemodynamic changes is sinusoidal dilation and </text>
<text top="1066" left="106" width="334" height="19" font="3">fluid filtering to the interstitial level. The filtrated </text>
<text top="1085" left="106" width="330" height="19" font="3">fluid passes through the hepatic capsule when lym-</text>
<text top="1104" left="106" width="334" height="19" font="3">phatic drainage capacity is exceeded. This process </text>
<text top="1122" left="106" width="334" height="19" font="3">leads to hepatic congestion, upper abdominal pain </text>
<text top="1141" left="106" width="335" height="19" font="3">and ascites. Portal pressure increases and hepatic </text>
<text top="557" left="457" width="334" height="19" font="3">perfusion decreases. The combined effect of these </text>
<text top="576" left="457" width="334" height="19" font="3">changes in the circulation is hypoxic injury of the </text>
<text top="595" left="457" width="335" height="19" font="3">hepatocytes, non-inflammatory centrolobular cell </text>
<text top="613" left="457" width="322" height="19" font="3">necrosis being found in about 70% of the cases</text>
<text top="614" left="778" width="5" height="11" font="6">1</text>
<text top="613" left="783" width="8" height="19" font="3">. </text>
<text top="632" left="457" width="335" height="19" font="3">Reperfusion-induced injury might also contribute </text>
<text top="651" left="457" width="330" height="19" font="3">to hepatocyte damage. Hepatocyte necrosis is associ-</text>
<text top="670" left="457" width="334" height="19" font="3">ated with the release of free radicals and secondary </text>
<text top="689" left="457" width="329" height="19" font="3">inflammation. A fulminant evolution of these patho-</text>
<text top="708" left="457" width="333" height="19" font="3">logic processes is generally rare, as it is chronic. Both </text>
<text top="727" left="457" width="329" height="19" font="3">acute and chronic forms result in massive centrolob-</text>
<text top="745" left="457" width="334" height="19" font="3">ular congestion, necrosis and atrophy. A few weeks </text>
<text top="764" left="457" width="333" height="19" font="3">after  obstruction,  fibrosis  appears,  mostly  in  the </text>
<text top="783" left="457" width="334" height="19" font="3">centrolobular area, and after a few months, nodular </text>
<text top="802" left="457" width="333" height="19" font="3">regeneration can be observed in the peri-portal area. </text>
<text top="821" left="457" width="334" height="19" font="3">The disease is characterized by progressive fibrosis, </text>
<text top="840" left="457" width="290" height="19" font="3">cirrhosis and nodular regenerative hyperplasia</text>
<text top="840" left="747" width="5" height="11" font="6">1</text>
<text top="840" left="751" width="4" height="19" font="3">.</text>
<text top="880" left="457" width="11" height="18" font="1">P</text>
<text top="884" left="468" width="46" height="13" font="0">OSITIVE</text>
<text top="880" left="514" width="5" height="18" font="1"> </text>
<text top="884" left="520" width="65" height="13" font="0">DIAGNOSIS</text>
<text top="915" left="487" width="300" height="19" font="3">Positive diagnosis is based on corroborating in-</text>
<text top="934" left="457" width="329" height="19" font="3">formation obtained from the patient’s medical his-</text>
<text top="953" left="457" width="329" height="19" font="3">tory and clinical examination with the laboratory in-</text>
<text top="972" left="457" width="333" height="19" font="3">vestigations. The most common signs and symptoms </text>
<text top="990" left="457" width="333" height="19" font="3">found in patients with BCS include fever, abdominal </text>
<text top="1009" left="457" width="329" height="19" font="3">pain and abdominal tenderness on palpation, hepa-</text>
<text top="1028" left="457" width="330" height="19" font="3">tomegaly, ascites, edema of the lower limbs, gastroin-</text>
<text top="1047" left="457" width="288" height="19" font="3">testinal bleeding and hepatic encephalopathy</text>
<text top="1048" left="744" width="9" height="11" font="6">11</text>
<text top="1047" left="753" width="38" height="19" font="3">. The </text>
<text top="1066" left="457" width="329" height="19" font="3">classical triad consists of abdominal pain, hepatomeg-</text>
<text top="1085" left="457" width="334" height="19" font="3">aly and ascites. Abdominal pain is present in 61% of </text>
<text top="1104" left="457" width="306" height="19" font="3">patients, hepatomegaly in 83% and ascites in 67%</text>
<text top="1104" left="762" width="20" height="11" font="6">12,13</text>
<text top="1104" left="783" width="8" height="19" font="3">. </text>
<text top="1122" left="457" width="333" height="19" font="3">BCS presentation may be acute, sub-acute or chronic, </text>
<text top="1141" left="457" width="334" height="19" font="3">the last two being the most common. The severity </text>
<text top="123" left="127" width="642" height="17" font="10"><b>Table 1.</b> Risk factors for Budd-Chiari syndrome (adapted after Podolsky DK, Kalloo AN, Camilleri M, </text>
<text top="142" left="123" width="646" height="17" font="9">Shanahan F, Fitz JG, Wang TC, Yamada’s Textbook of Gastroenterology Sixth edition, 2016: 2172–2175).</text>
<text top="166" left="111" width="177" height="15" font="8">Primary Budd–Chiari syndrome</text>
<text top="166" left="522" width="190" height="15" font="8">Secondary Budd–Chiari syndrome</text>
<text top="187" left="111" width="186" height="15" font="8">Acquired prothrombotic diseases:</text>
<text top="200" left="111" width="248" height="17" font="8">Myeloproliferative neoplasms (28%–49%)</text>
<text top="215" left="111" width="27" height="17" font="8"></text>
<text top="217" left="124" width="162" height="15" font="8">Antiphospholipid antibodies </text>
<text top="217" left="286" width="56" height="15" font="8">(5%–25%)</text>
<text top="232" left="124" width="62" height="15" font="8">paroxysmal</text>
<text top="245" left="111" width="331" height="17" font="8">Paroxysmal nocturnal hemoglobinuria (PNH) (9%–19%)</text>
<text top="260" left="111" width="173" height="17" font="8">Behçet’s disease (0%–33%)*</text>
<text top="275" left="111" width="183" height="17" font="8">Hyperhomocysteinemia (37%)</text>
<text top="183" left="506" width="158" height="17" font="8">Hepatocellular carcinoma</text>
<text top="198" left="506" width="131" height="17" font="8">Renal cell carcinoma</text>
<text top="213" left="506" width="120" height="17" font="8">Adrenal carcinoma</text>
<text top="228" left="506" width="209" height="17" font="8">Primary hepatic hemangiosarcoma</text>
<text top="243" left="506" width="209" height="17" font="8">Epithelioid hemangioendothelioma</text>
<text top="258" left="506" width="202" height="17" font="8">Sarcoma of the inferior vena cava</text>
<text top="273" left="506" width="129" height="17" font="8">Right atrial myxoma</text>
<text top="288" left="506" width="89" height="17" font="8">Hydatid cysts</text>
<text top="303" left="506" width="172" height="17" font="8">Amebic or pyogenic abscess</text>
<text top="318" left="506" width="77" height="17" font="8">Sarcoidosis</text>
<text top="333" left="506" width="56" height="17" font="8">Trauma</text>
<text top="348" left="506" width="88" height="17" font="8">Aspergillosis</text>
<text top="363" left="506" width="122" height="17" font="8">Abdominal surgery</text>
<text top="297" left="111" width="186" height="15" font="8">Inherited prothrombotic diseases:</text>
<text top="311" left="111" width="216" height="17" font="8">Factor V Leiden mutation (7%–32%)</text>
<text top="326" left="111" width="190" height="17" font="8">Protein C deficiency (4%–30%)</text>
<text top="341" left="111" width="189" height="17" font="8">Protein S deficiency (3%–20%)</text>
<text top="356" left="111" width="212" height="17" font="8">Antithrombin deficiency (3%–23%)</text>
<text top="371" left="111" width="253" height="17" font="8">Prothrombin G20210A mutation (3%–12%)</text>
<text top="386" left="111" width="27" height="17" font="8"></text>
<text top="387" left="124" width="302" height="15" font="8">Methylene-tetrahydrofolate reductase gene mutations </text>
<text top="402" left="124" width="184" height="15" font="8">(MTHFR mutations) (12%–22%)</text>
<text top="423" left="111" width="74" height="15" font="8">Other causes:</text>
<text top="436" left="111" width="186" height="17" font="8">Oral contraceptives (6%–60%)</text>
<text top="451" left="111" width="204" height="17" font="8">Pregnancy, puerperium (6%–12%)</text>
<text top="466" left="111" width="176" height="17" font="8">Hypereosinophilic syndrome</text>
<text top="481" left="111" width="142" height="17" font="8">Granulomatis venulitis</text>
<text top="496" left="111" width="109" height="17" font="8">Ulcerative colitis</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1262" width="892">
<text top="91" left="106" width="242" height="14" font="8">Budd-Chiari syndrome – GHEORGHE et al</text>
<text top="1182" left="106" width="143" height="14" font="8">348  /  vol. 54, no. 2</text>
<text top="126" left="106" width="334" height="19" font="3">of symptoms depends on the extent of the lesion in </text>
<text top="145" left="106" width="329" height="19" font="3">the hepatic veins, the time passed after the appear-</text>
<text top="164" left="106" width="329" height="19" font="3">ance of the obstruction and the duration of the dis-</text>
<text top="182" left="106" width="334" height="19" font="3">ease remaining untreated. A slower development in </text>
<text top="201" left="106" width="334" height="19" font="3">the obstruction leads to the formation of collateral </text>
<text top="220" left="106" width="335" height="19" font="3">vessels, which improves the sinusoidal congestion. </text>
<text top="239" left="106" width="334" height="19" font="3">Patients with acute presentation are more prone to </text>
<text top="257" left="106" width="330" height="19" font="3">have a fulminant evolution, with liver failure, coagu-</text>
<text top="276" left="106" width="333" height="19" font="3">lopathy, encephalopathy, and hepato-renal syndrome. </text>
<text top="295" left="106" width="334" height="19" font="3">However, in a chronic evolution with well-developed </text>
<text top="314" left="106" width="329" height="19" font="3">collateral vessels or the involvement of a single he-</text>
<text top="332" left="106" width="330" height="19" font="3">patic vein, the patient may have preserved liver func-</text>
<text top="351" left="106" width="334" height="19" font="3">tion. Patients with obstruction of the inferior vena </text>
<text top="370" left="106" width="333" height="19" font="3">cava may present a sub-cutaneous venous network on </text>
<text top="389" left="106" width="330" height="19" font="3">the abdomen, anterior thorax and back, which repre-</text>
<text top="407" left="106" width="334" height="19" font="3">sents the so-called collateral circulation. Portal vein </text>
<text top="426" left="106" width="330" height="19" font="3">thrombosis is present in approximately 15% of pa-</text>
<text top="445" left="106" width="100" height="19" font="3">tients with BCS</text>
<text top="446" left="206" width="16" height="11" font="6">2,14</text>
<text top="445" left="221" width="214" height="19" font="3">. These patients have a high preva-</text>
<text top="464" left="106" width="333" height="19" font="3">lence of multiple risk factors and a reserved prognosis </text>
<text top="482" left="106" width="333" height="19" font="3">compared to patients with isolated BCS. Also, up to </text>
<text top="501" left="106" width="234" height="19" font="3">20% of patients may be asymptomatic</text>
<text top="502" left="341" width="5" height="11" font="6">2</text>
<text top="501" left="346" width="94" height="19" font="3">. For a positive </text>
<text top="520" left="106" width="333" height="19" font="3">diagnosis, both laboratory investigations and imaging </text>
<text top="539" left="106" width="329" height="19" font="3">investigations are necessary. Thus, serum aminotrans-</text>
<text top="557" left="106" width="334" height="19" font="3">ferases and alkaline phosphatase may be normal or </text>
<text top="576" left="106" width="51" height="19" font="3">elevated</text>
<text top="577" left="157" width="5" height="11" font="6">2</text>
<text top="576" left="162" width="274" height="19" font="3">. In acute forms, the aminotransferases lev-</text>
<text top="595" left="106" width="233" height="19" font="3">els exceed 5 times the normal value</text>
<text top="596" left="339" width="5" height="11" font="6">1</text>
<text top="595" left="343" width="97" height="19" font="3">. Prothrombin </text>
<text top="614" left="106" width="333" height="19" font="3">and bilirubin values may also be normal or increased, </text>
<text top="632" left="106" width="333" height="19" font="3">although the presence of jaundice in BCS is not very </text>
<text top="651" left="106" width="329" height="19" font="3">frequent. The levels of albumin can be moderately de-</text>
<text top="670" left="106" width="333" height="19" font="3">creased and the serum-ascites albumin ratio is greater </text>
<text top="689" left="106" width="85" height="19" font="3">than 1.1 g/dL</text>
<text top="689" left="191" width="5" height="11" font="6">2</text>
<text top="689" left="196" width="243" height="19" font="3">. The low levels of protein C, protein S </text>
<text top="707" left="106" width="333" height="19" font="3">or antithrombin can be misleading, because they can </text>
<text top="726" left="106" width="334" height="19" font="3">be the mark of both a coagulopathy and of chronic </text>
<text top="745" left="106" width="313" height="19" font="3">liver disease development in the evolution of BCS</text>
<text top="746" left="419" width="5" height="11" font="6">2</text>
<text top="745" left="424" width="4" height="19" font="3">.</text>
<text top="764" left="136" width="304" height="19" font="3">In almost all cases, the diagnosis of BCS can be </text>
<text top="782" left="106" width="334" height="19" font="3">determined by non-invasive imaging methods, such </text>
<text top="801" left="106" width="335" height="19" font="3">as Doppler ultrasound, CT, or MRI-angiography. </text>
<text top="820" left="106" width="334" height="19" font="3">Current guidelines recommend performing either a </text>
<text top="839" left="106" width="334" height="19" font="3">CT scan or an MRI to confirm the diagnosis only </text>
<text top="857" left="106" width="211" height="19" font="3">if the ultrasound is not available</text>
<text top="858" left="317" width="9" height="11" font="6">15</text>
<text top="857" left="326" width="109" height="19" font="3">. Imaging evalua-</text>
<text top="876" left="106" width="333" height="19" font="3">tion may reveal obstruction or lack of blood flow in a </text>
<text top="895" left="106" width="334" height="19" font="3">major liver vein or in the intrahepatic portion of the </text>
<text top="914" left="106" width="330" height="19" font="3">inferior vena cava, the formation of collateral vascu-</text>
<text top="932" left="106" width="330" height="19" font="3">lar networks, a nodular aspect of the hepatic paren-</text>
<text top="951" left="106" width="333" height="19" font="3">chyma, increased size of the caudate lobe, ascites and </text>
<text top="970" left="106" width="85" height="19" font="3">splenomegaly</text>
<text top="971" left="190" width="5" height="11" font="6">2</text>
<text top="970" left="195" width="245" height="19" font="3">. If the hepatic veins are perceived as </text>
<text top="989" left="106" width="333" height="19" font="3">normal, with usual blood flow, the diagnosis of BCS </text>
<text top="1007" left="106" width="329" height="19" font="3">is excluded. Ultrasound is superior to MRI in detect-</text>
<text top="1026" left="106" width="321" height="19" font="3">ing the intrahepatic collateral vascular networks</text>
<text top="1027" left="427" width="5" height="11" font="6">2</text>
<text top="1026" left="432" width="8" height="19" font="3">. </text>
<text top="1045" left="106" width="333" height="19" font="3">Liver biopsy is of limited value, due to the variability </text>
<text top="1064" left="106" width="63" height="19" font="3">of injuries</text>
<text top="1064" left="168" width="9" height="11" font="6">16</text>
<text top="1064" left="178" width="261" height="19" font="3">. However, biopsy is the only method that </text>
<text top="1082" left="106" width="334" height="19" font="3">can establish the diagnosis of BCS when lesions are </text>
<text top="1101" left="106" width="247" height="19" font="3">located in the small intrahepatic veins</text>
<text top="1102" left="352" width="9" height="11" font="6">16</text>
<text top="1101" left="361" width="79" height="19" font="3">. Currently, </text>
<text top="1120" left="106" width="330" height="19" font="3">the development of radiological diagnostic means re-</text>
<text top="1139" left="106" width="333" height="19" font="3">sulted in limiting the use of invasive methods, such </text>
<text top="126" left="457" width="333" height="19" font="3">as venography or liver biopsy, in patients in whom the </text>
<text top="145" left="457" width="329" height="19" font="3">diagnosis remains uncertain or in order to character-</text>
<text top="164" left="457" width="216" height="19" font="3">ize the anatomy prior to treatment</text>
<text top="164" left="673" width="20" height="11" font="6">16-18</text>
<text top="164" left="693" width="4" height="19" font="3">.</text>
<text top="182" left="487" width="305" height="19" font="3">The presence of liver regeneration nodules is </text>
<text top="201" left="457" width="333" height="19" font="3">common in patients with BCS. Since these patients </text>
<text top="220" left="457" width="329" height="19" font="3">are also exposed to a greater risk of developing hepa-</text>
<text top="239" left="457" width="329" height="19" font="3">tocellular carcinoma, it is very important to differen-</text>
<text top="257" left="457" width="280" height="19" font="3">tiate between benign and malignant nodules</text>
<text top="258" left="737" width="20" height="11" font="6">16-19</text>
<text top="257" left="757" width="4" height="19" font="3">.</text>
<text top="276" left="487" width="304" height="19" font="3">BCS patients may have similar features to those </text>
<text top="295" left="457" width="335" height="19" font="3">with heart disease and tricuspid regurgitation or </text>
<text top="314" left="457" width="149" height="19" font="3">constrictive pericarditis</text>
<text top="314" left="606" width="21" height="11" font="6">20,21</text>
<text top="314" left="627" width="164" height="19" font="3">. Thus, if the presence of </text>
<text top="332" left="457" width="333" height="19" font="3">cardiac disorders is suspected, it is necessary to make </text>
<text top="351" left="457" width="330" height="19" font="3">a differential diagnosis, most commonly using echo-</text>
<text top="370" left="457" width="81" height="19" font="3">cardiography</text>
<text top="371" left="537" width="16" height="11" font="6">1,22</text>
<text top="370" left="553" width="4" height="19" font="3">.</text>
<text top="389" left="487" width="304" height="19" font="3">In addition to the positive diagnosis of BCS, it </text>
<text top="407" left="457" width="334" height="19" font="3">is necessary to identify the predisposing factors. In </text>
<text top="426" left="457" width="334" height="19" font="3">about half of the cases, multiple factors are present. </text>
<text top="445" left="457" width="330" height="19" font="3">Thus, it is recommended that a complete epidemio-</text>
<text top="464" left="457" width="329" height="19" font="3">logical study be performed, even after the first identi-</text>
<text top="482" left="457" width="142" height="19" font="3">fication of a risk factor</text>
<text top="483" left="599" width="5" height="11" font="6">2</text>
<text top="482" left="604" width="4" height="19" font="3">.</text>
<text top="522" left="457" width="10" height="18" font="1">T</text>
<text top="526" left="466" width="65" height="13" font="0">REATMENT</text>
<text top="522" left="531" width="5" height="18" font="1"> </text>
<text top="526" left="536" width="15" height="13" font="0">OF</text>
<text top="522" left="552" width="5" height="18" font="1"> </text>
<text top="526" left="557" width="34" height="13" font="0">BUDD</text>
<text top="522" left="592" width="4" height="18" font="1">-</text>
<text top="526" left="597" width="41" height="13" font="0">CHIARI</text>
<text top="522" left="639" width="5" height="18" font="1"> </text>
<text top="526" left="644" width="68" height="13" font="0">SYNDROME</text>
<text top="557" left="487" width="304" height="19" font="3">The management of patients with BCS involves </text>
<text top="576" left="457" width="121" height="19" font="3">the following steps:</text>
<text top="593" left="457" width="330" height="20" font="3">.  Anticoagulant treatment of the prothrombotic con-</text>
<text top="614" left="472" width="318" height="19" font="3">ditions that led to BCS, prevention or treatment of </text>
<text top="632" left="472" width="236" height="19" font="3">complications of portal hypertension.</text>
<text top="649" left="457" width="234" height="20" font="3">.  Angioplasty, with or without stent.</text>
<text top="668" left="457" width="335" height="20" font="3">.  Trans-jugular intrahepatic portosystemic shunt </text>
<text top="689" left="472" width="319" height="19" font="3">(TIPS), if angioplasty is not available or has not </text>
<text top="707" left="472" width="86" height="19" font="3">been effective</text>
<text top="708" left="558" width="21" height="11" font="6">23,24</text>
<text top="707" left="579" width="4" height="19" font="3">.</text>
<text top="724" left="457" width="329" height="20" font="3">.  Evaluation for liver transplant if TIPS proved inef-</text>
<text top="745" left="472" width="39" height="19" font="3">ficient</text>
<text top="746" left="512" width="16" height="11" font="6">2,10</text>
<text top="745" left="528" width="4" height="19" font="3">.</text>
<text top="764" left="487" width="305" height="19" font="3">Anticoagulant therapy is recommended to all </text>
<text top="782" left="457" width="333" height="19" font="3">patients with BCS, even to those that do not have </text>
<text top="801" left="457" width="334" height="19" font="3">a prothrombotic factor or who are asymptomatic, in </text>
<text top="820" left="457" width="329" height="19" font="3">the absence of possible adverse reactions. The antico-</text>
<text top="839" left="457" width="334" height="19" font="3">agulation objective is to reduce the risk of thrombus </text>
<text top="857" left="457" width="300" height="19" font="3">extension and prevent new thrombotic episodes</text>
<text top="858" left="757" width="17" height="11" font="6">2,25</text>
<text top="857" left="773" width="4" height="19" font="3">.</text>
<text top="876" left="487" width="300" height="19" font="3">The data on the benefits of thrombolysis in pa-</text>
<text top="895" left="457" width="330" height="19" font="3">tients with BCS are insufficient. Current studies sug-</text>
<text top="914" left="457" width="329" height="19" font="3">gest that the best results are obtained by local injec-</text>
<text top="932" left="457" width="334" height="19" font="3">tion of the thrombolytic agent, rather than systemic </text>
<text top="951" left="457" width="334" height="19" font="3">thrombolysis, in the case of incomplete and recent </text>
<text top="970" left="457" width="70" height="19" font="3">thrombosis</text>
<text top="971" left="527" width="9" height="11" font="6">26</text>
<text top="970" left="536" width="4" height="19" font="3">.</text>
<text top="989" left="487" width="304" height="19" font="3">Angioplasty, with or without stent, should be </text>
<text top="1007" left="457" width="334" height="19" font="3">considered in patients with a short stenosis. Better </text>
<text top="1026" left="457" width="329" height="19" font="3">results are obtained if anticoagulant therapy is con-</text>
<text top="1045" left="457" width="174" height="19" font="3">tinued for at least 6 months</text>
<text top="1046" left="631" width="9" height="11" font="6">27</text>
<text top="1045" left="640" width="4" height="19" font="3">.</text>
<text top="1064" left="487" width="300" height="19" font="3">The use of TIPS in patients with BCS has recent-</text>
<text top="1082" left="457" width="334" height="19" font="3">ly seen an increase. Current guidelines recommend </text>
<text top="1101" left="457" width="333" height="19" font="3">consideration of TIPS in patients who did not show a </text>
<text top="1120" left="457" width="333" height="19" font="3">significant improvement on anticoagulant treatment. </text>
<text top="1139" left="457" width="333" height="19" font="3">Morbidity and mortality are lower in the case of TIPS </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="11" size="11" family="Times" color="#231f20"/>
	<fontspec id="12" size="11" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="8">Archives of the Balkan Medical Union</text>
<text top="1182" left="661" width="42" height="14" font="8">June </text>
<text top="1182" left="693" width="94" height="14" font="8">2019 / 349</text>
<text top="126" left="106" width="330" height="19" font="3">than in surgical shunts. On the other hand, the hem-</text>
<text top="145" left="106" width="333" height="19" font="3">orrhagic complications of TIPS are more common in </text>
<text top="164" left="106" width="334" height="19" font="3">patients with BCS than other chronic liver diseases, </text>
<text top="183" left="106" width="316" height="19" font="3">but the incidence of encephalopathy can be less</text>
<text top="184" left="422" width="9" height="11" font="6">28</text>
<text top="183" left="432" width="8" height="19" font="3">. </text>
<text top="202" left="106" width="334" height="19" font="3">Liver transplant is the elective treatment in patients </text>
<text top="221" left="106" width="333" height="19" font="3">with acute BCS and fulminant hepatic failure and in </text>
<text top="240" left="106" width="329" height="19" font="3">patients that get to the final stage after a chronic evo-</text>
<text top="259" left="106" width="38" height="19" font="3">lution</text>
<text top="259" left="145" width="21" height="11" font="6">29,30</text>
<text top="259" left="166" width="274" height="19" font="3">. Recent data suggest that liver transplant </text>
<text top="278" left="106" width="334" height="19" font="3">increases 1-year survival rates up to 75% and up to </text>
<text top="297" left="106" width="92" height="19" font="3">65% in 5 years</text>
<text top="297" left="199" width="9" height="11" font="6">31</text>
<text top="297" left="207" width="4" height="19" font="3">.</text>
<text top="316" left="136" width="300" height="19" font="3">BCS prognosis varies depending on the under-</text>
<text top="335" left="106" width="334" height="19" font="3">lying condition. The treatment is aimed at slowing </text>
<text top="353" left="106" width="334" height="19" font="3">disease progression and improving patients’ quality </text>
<text top="372" left="106" width="334" height="19" font="3">of life. Being subjected to a higher risk of infection, </text>
<text top="391" left="106" width="334" height="19" font="3">it is important that these patients should be advised </text>
<text top="410" left="106" width="329" height="19" font="3">regarding personal hygiene and influenza or pneumo-</text>
<text top="429" left="106" width="334" height="19" font="3">coccal vaccination. Also, taking into consideration </text>
<text top="448" left="106" width="330" height="19" font="3">the psychological impact of this disease, it is neces-</text>
<text top="467" left="106" width="201" height="19" font="3">sary to provide a support system</text>
<text top="468" left="308" width="5" height="11" font="6">3</text>
<text top="467" left="312" width="4" height="19" font="3">.</text>
<text top="507" left="106" width="12" height="18" font="1">C</text>
<text top="511" left="118" width="77" height="13" font="0">ONCLUSIONS</text>
<text top="543" left="136" width="305" height="19" font="3">BCS is a rare disease with a severe prognosis, </text>
<text top="561" left="106" width="329" height="19" font="3">if not properly diagnosed and treated. The identi-</text>
<text top="580" left="106" width="334" height="19" font="3">fication of risk factors is helpful for the diagnosis. </text>
<text top="599" left="106" width="335" height="19" font="3">Modern treatments, including the interventional </text>
<text top="618" left="106" width="335" height="19" font="3">ones, may improve the prognosis of patients with </text>
<text top="637" left="106" width="294" height="19" font="3">BCS, depending on the etiology of the disease.</text>
<text top="698" left="106" width="267" height="15" font="9">Compliance with Ethics Requirements:</text>
<text top="713" left="136" width="304" height="19" font="7"><i>„The authors declare no conflict of interest regarding </i></text>
<text top="732" left="106" width="65" height="19" font="7"><i>this article“</i></text>
<text top="791" left="106" width="12" height="18" font="1">R</text>
<text top="794" left="118" width="71" height="13" font="0">EFERENCES</text>
<text top="826" left="106" width="329" height="15" font="8">1.  Aydinli M, Bayraktar Y. Budd-Chiari syndrome: etiol-</text>
<text top="842" left="128" width="311" height="15" font="8">ogy, pathogenesis and diagnosis. <i>World J Gastroenterol</i> </text>
<text top="857" left="128" width="124" height="15" font="8">2007;13(19):2693–2696.</text>
<text top="873" left="106" width="333" height="15" font="8">2.  Podolsky DK, Kalloo AN, Camilleri M, Shanahan F, Fitz </text>
<text top="889" left="128" width="313" height="15" font="8">JG, Wang TC. Yamada’s Textbook of Gastroenterology. </text>
<text top="905" left="128" width="252" height="15" font="8">Wiley-Blackwell, Sixth edition, 2016: 2172–2175.</text>
<text top="921" left="106" width="333" height="15" font="8">3.  Khan F, Armstrong MJ, Mehrzad H, et al. Review article: </text>
<text top="937" left="128" width="308" height="15" font="8">a multidisciplinary approach to the diagnosis and manage-</text>
<text top="953" left="128" width="312" height="15" font="8">ment of Budd-Chiari syndrome. <i>Alimentary Pharmacology&amp; </i></text>
<text top="969" left="128" width="161" height="15" font="11"><i>Therapeutics</i><b>. 2019;49:840-863.</b></text>
<text top="985" left="106" width="333" height="15" font="8">4.  Valla DC. Budd-Chiary syndrome/hepatic venous outflow </text>
<text top="1001" left="128" width="290" height="15" font="8">tract obstruction. <i>Hepatol Int.</i> 2018;12(Suppl 1):168-180.</text>
<text top="1017" left="106" width="332" height="15" font="8">5.  Shrestha SM, Joshi BL, Shrestha S, et al. Cavographic study </text>
<text top="1033" left="128" width="311" height="15" font="8">of inferior vena cava obstruction. Cavographic study of an </text>
<text top="1049" left="128" width="308" height="15" font="8">early stage of obstruction of the hepatic portion of the infe-</text>
<text top="1065" left="128" width="263" height="15" font="8">rior vena cava. <i>J Gastroenterol Hepatol</i> 2000;15<b>:</b>202.</text>
<text top="1081" left="106" width="329" height="15" font="8">6.  Denninger MH, Chait Y, Casadevall N, et al. Cause of por-</text>
<text top="1097" left="128" width="308" height="15" font="8">tal or hepatic venous thrombosis in adults: the role of mul-</text>
<text top="1113" left="128" width="252" height="15" font="8">tiple concurrent factors. <i>Hepatology</i> 2000;31:587.</text>
<text top="1129" left="106" width="332" height="15" font="8">7.  Moisa C, Gaman MA, Diaconu C, Assani AD, Gaman AM. </text>
<text top="1144" left="128" width="312" height="15" font="8">The evaluation of oxidative stress in patients wih essential </text>
<text top="126" left="478" width="311" height="15" font="8">thrombocythemia treated with risk-adapted therapy. <i>Arch </i></text>
<text top="142" left="478" width="184" height="15" font="11"><i>Balk Med Union</i> 2018;53(4):529-534.</text>
<text top="158" left="457" width="332" height="15" font="8">8.  Primignani M, Mannucci PM. The role of thrombophilia in </text>
<text top="175" left="478" width="297" height="15" font="8">splanchnic vein thrombosis. <i>Semin Liver Dis</i> 2008;28:293.</text>
<text top="191" left="457" width="329" height="15" font="8">9.  Diaconu  C,  Balaceanu  A,  Bartos  D.  Venous  thrombo-</text>
<text top="207" left="478" width="311" height="15" font="8">embolism  in  patients  with  cancer.  <i>Medicine in Evolution</i> </text>
<text top="223" left="478" width="104" height="15" font="8">2014;XX(2):187-194.</text>
<text top="239" left="457" width="329" height="15" font="8">10.  Talens S, Hoekstra J, Dirkx SP, et al. Proteomic analysis re-</text>
<text top="255" left="478" width="311" height="15" font="8">veals that apolipoprotein A1 levels are decreased in patients </text>
<text top="272" left="478" width="268" height="15" font="8">with Budd-Chiari syndrome. <i>J Hepatol</i> 2011;54:908.</text>
<text top="288" left="457" width="333" height="15" font="8">11.  Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. </text>
<text top="304" left="478" width="308" height="15" font="8">Etiology, management, and outcome of the Budd-Chiari syn-</text>
<text top="320" left="478" width="209" height="15" font="8">drome. <i>Ann Intern Med</i> 2009;151<b>:</b>167-175</text>
<text top="336" left="457" width="330" height="15" font="8">12.   Shin N, Kim YH, Xu H, et al. Redefining Budd-Chiari syn-</text>
<text top="352" left="478" width="308" height="15" font="8">drome: a systematic review. <i>World J Hepatol</i>. 2016;8:691-702.</text>
<text top="369" left="457" width="329" height="15" font="8">13.  Bogin  V,  Marcos  A,  Shaw-Stiffel  T,  Budd-Chiari  syn-</text>
<text top="385" left="478" width="312" height="15" font="8">drome: in evolution. <i>European Journal of Gastroenterology &amp; </i></text>
<text top="401" left="478" width="143" height="15" font="11"><i>Hepatology</i> 2005;17(1):33-35.</text>
<text top="417" left="457" width="336" height="15" font="8">14. Darwish Murad S, Valla DC, de Groen PC, et al. </text>
<text top="433" left="478" width="313" height="15" font="8">Pathogenesis and treatment of Budd-Chiari syndrome </text>
<text top="449" left="478" width="311" height="15" font="8">combined with portal vein thrombosis. <i>Am J Gastroenterol</i> </text>
<text top="466" left="478" width="67" height="15" font="8">2006;101:83.</text>
<text top="482" left="457" width="332" height="15" font="8">15.  De Leve LD, Valla DC, Garcia-Tsao G. Vascular disorders of </text>
<text top="498" left="478" width="178" height="15" font="8">the liver. <i>Hepatology</i> 2009;49<b>:</b>1729.</text>
<text top="514" left="457" width="333" height="15" font="8">16.  Flor N, Zuin M, Brovelli F, et al. Regenerative nodules in </text>
<text top="530" left="478" width="308" height="15" font="8">patients with chronic Budd-Chiari syndrome: a longitudi-</text>
<text top="546" left="478" width="311" height="15" font="8">nal study using multiphase contrast-enhanced multidetector </text>
<text top="563" left="478" width="152" height="15" font="8">CT. <i>Eur J Radiol</i> 2010;73:588.</text>
<text top="579" left="457" width="332" height="15" font="8">17.  Balaceanu A, Diaconu C, Aron G. Budd-Chiari syndrome as </text>
<text top="595" left="478" width="312" height="15" font="8">an initial presentation of hepatocellular carcinoma – a case </text>
<text top="611" left="478" width="260" height="15" font="8">report. <i>Medical Ultrasonography</i> 2014;16(2):172-174.</text>
<text top="627" left="457" width="333" height="15" font="8">18.  Ilie  M,  Rusu  M,  Rosianu  C,  et  al.  Ultrasound-guided </text>
<text top="643" left="478" width="311" height="15" font="8">biopsy in focal liver lesions. <i>Arch Balk Med Union</i> </text>
<text top="660" left="478" width="102" height="15" font="8">2018;53(3):364-368.</text>
<text top="676" left="457" width="336" height="15" font="8">19. Balaceanu A, Diaconu C, Mateescu D, Stanica A. </text>
<text top="692" left="478" width="308" height="15" font="8">Hepatocellular carcinoma with hepatic and pulmonary me-</text>
<text top="708" left="478" width="308" height="15" font="8">tastasis, inferior vena cava and left pulmonary artery throm-</text>
<text top="724" left="478" width="308" height="15" font="8">bosis in a patient with asymptomatic hepatitis C. Case re-</text>
<text top="740" left="478" width="253" height="15" font="8">port. <i>Medical Ultrasonography</i> 2010;12(4):345-348<i>.</i></text>
<text top="757" left="457" width="329" height="15" font="8">20. Draghici T, Negreanu L, Bratu OG, et al. Liver abnor-</text>
<text top="773" left="478" width="311" height="15" font="8">malities in patients with heart failure. <i>Arch Balk Med Union</i> </text>
<text top="789" left="478" width="88" height="15" font="8">2018;53(1):76-81.</text>
<text top="805" left="457" width="333" height="15" font="8">21.  Diaconu C, Mateescu D, Balaceanu A, Marcu M, Jianu V, </text>
<text top="821" left="478" width="311" height="15" font="8">Stanica A. Pancreatic cancer presenting with paraneoplastic </text>
<text top="837" left="478" width="312" height="15" font="8">thrombophlebitis: a case report. <i>Journal of Medicine and Life </i></text>
<text top="854" left="478" width="86" height="15" font="8">2010;3(1): 96-99.</text>
<text top="870" left="457" width="334" height="15" font="8">22. Paraschiv B, Dediu G, Iancu A, Bratu O, Diaconu C. </text>
<text top="886" left="478" width="311" height="15" font="8">Superior vena cava syndrome – review. <i>Arch Balk Med Union</i> </text>
<text top="902" left="478" width="87" height="15" font="8">2017;52(1):39-43.</text>
<text top="918" left="457" width="333" height="15" font="8">23.  Tripathi D, Macnicholas R, Kothari C, et al. Good clinical </text>
<text top="934" left="478" width="311" height="15" font="8">outcomes following trans-jugular intrahepatic portosystemic </text>
<text top="950" left="478" width="311" height="15" font="8">stent-shunts in Budd-Chiari syndrome. <i>Aliment Pharmacol</i>. </text>
<text top="967" left="478" width="90" height="15" font="8">2014;39:864-872.</text>
<text top="983" left="457" width="332" height="15" font="8">24.  Hayek G, Ronot M, Plessier A, et al. Long-term outcome and </text>
<text top="999" left="478" width="308" height="15" font="8">analysis of dysfunction of trans-jugular intrahepatic porto-</text>
<text top="1015" left="478" width="312" height="15" font="8">systemic shunt placement in chronic primary Budd-Chiari </text>
<text top="1031" left="478" width="205" height="15" font="8">syndrome. <i>Radiology.</i> 2017;283:280-292.</text>
<text top="1047" left="457" width="333" height="15" font="8">25.  De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic </text>
<text top="1064" left="478" width="311" height="15" font="8">treatment with direct-acting oral anticoagulants in patients </text>
<text top="1080" left="478" width="311" height="15" font="8">with splanchnic vein thrombosis and cirrhosis. <i>Liver Int</i>. </text>
<text top="1096" left="478" width="87" height="15" font="8">2017;37:694-699.</text>
<text top="1112" left="457" width="334" height="15" font="8">26. Sharma S, Texeira A, Texeira P, et al. Pharmacological </text>
<text top="1128" left="478" width="308" height="15" font="8">thrombolysis in Budd Chiari syndrome: a single centre ex-</text>
<text top="1144" left="478" width="308" height="15" font="8">perience and review of the literature. <i>J Hepatol</i> 2004;40<b>:</b>172.</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1262" width="892">
<text top="91" left="106" width="242" height="14" font="8">Budd-Chiari syndrome – GHEORGHE et al</text>
<text top="1182" left="106" width="143" height="14" font="8">350  /  vol. 54, no. 2</text>
<text top="126" left="106" width="333" height="15" font="8">27.  Zhang CQ, Fu LN, Xu L, et al. Long-term effect of stent </text>
<text top="142" left="128" width="313" height="15" font="8">placement in 115 patients with Budd-Chiari syndrome. </text>
<text top="158" left="128" width="174" height="15" font="11"><i>World J Gastroenterol</i> 2003;9<b>:</b>2587.</text>
<text top="173" left="106" width="333" height="15" font="8">28.  De Leve LD, Kanel GC. Vascular diseases of the liver. In: </text>
<text top="189" left="128" width="312" height="15" font="8">Yamada T, Alpers DH, Kaplowitz N, et al. (eds). Atlas of </text>
<text top="205" left="128" width="312" height="15" font="8">Gastroenterology, 4th ed. Oxford: Blackwell Publishing; </text>
<text top="221" left="128" width="50" height="15" font="8">2009:731.</text>
<text top="236" left="106" width="333" height="15" font="8">29.  Potthoff A, Attia D, Pischke S, et al. Long-term outcome </text>
<text top="252" left="128" width="312" height="15" font="8">of  liver  transplant  patients  with  Budd-Chiari  syndrome </text>
<text top="126" left="478" width="311" height="15" font="8">secondary to myeloproliferative neoplasms. <i>Liver Int.</i> </text>
<text top="142" left="478" width="101" height="15" font="8">2015;35:2042-2049.</text>
<text top="158" left="457" width="333" height="15" font="8">30.  Diaconescu D, Pantea Stoian A, Socea L, et al. Hepato-renal </text>
<text top="173" left="478" width="308" height="15" font="8">syndrome: a review. <i>Arch Balk Med Union</i> 2018;53(2):239-245.</text>
<text top="189" left="457" width="332" height="15" font="8">31.  Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver </text>
<text top="205" left="478" width="308" height="15" font="8">transplantation for Budd-Chiari syndrome: a national regis-</text>
<text top="221" left="478" width="203" height="15" font="8">try analysis. <i>Liver Transpl</i> 2007;13:1285.</text>
</page>
</pdf2xml>
